What is the ROE (Return on Equity) of Newron Pharmaceuticals SpA this year?
The ROE of Newron Pharmaceuticals SpA this year is 0.54 undefined.
In 2024, Newron Pharmaceuticals SpA's return on equity (ROE) was 0.54, a -56.49% increase from the 1.25 ROE in the previous year.
Newron Pharmaceuticals SpA's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Analyzing Newron Pharmaceuticals SpA's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Newron Pharmaceuticals SpA's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Changes in Newron Pharmaceuticals SpA’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
The ROE of Newron Pharmaceuticals SpA this year is 0.54 undefined.
The ROE of Newron Pharmaceuticals SpA has increased by -56.49% decreased compared to the previous year.
A high ROE indicates that Newron Pharmaceuticals SpA generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
A low ROE can indicate that Newron Pharmaceuticals SpA is having difficulties monetizing its investments successfully and can be a negative signal for investors.
A change in ROE (Return on Equity) of Newron Pharmaceuticals SpA can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Some factors that can influence Newron Pharmaceuticals SpA's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.
The current dividend yield of Newron Pharmaceuticals SpA is .
Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .
Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
Newron Pharmaceuticals SpA is assigned to the 'Health' sector.
To receive the latest dividend of Newron Pharmaceuticals SpA from 10/28/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.
The last dividend was paid out on 10/28/2024.
In the year 2023, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.
The dividends of Newron Pharmaceuticals SpA are distributed in EUR.
Our stock analysis for Newron Pharmaceuticals SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Newron Pharmaceuticals SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.